FDA OKs Intravenous Tocilizumab Biosimilar in Cytokine Release Syndrome
The intravenous formulation of tocilizumab-anoh for CRS is expected to launch in the US on August 31, 2025.
Previous Post
Unique Psychological Burden of Fear of Progression Seen in MG
Next Post
Reducing Oxygen Intake Could Help Prevent — or Even Reverse — Symptoms of Parkinson’s Disease
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago